Gelesis Announces Three Presentations at Annual Endocrine Society Meeting
March 21 2019 - 3:00AM
Business Wire
Gelesis, a biotechnology company developing first-in-class
mechanotherapeutics to treat obesity and other chronic diseases
related to the gastrointestinal (GI) tract, today announced the
Company will deliver three poster presentations at ENDO, the
Endocrine Society Annual Meeting, held in New Orleans from March
23-26.
Two of the presentations will share expanded clinical data from
the pivotal study of Gelesis100, an oral, non-systemic approach to
weight loss. A third will highlight preclinical data suggesting a
different product candidate derived from Gelesis’ proprietary
hydrogel platform can restore gut barrier function in mice with
severe gut wall injury.
“We are pleased to share expanded clinical data which seeks to
address crucial public health issues associated with overweight and
obesity. We are also excited to present our latest research on
leveraging our hydrogel technology in chronic diseases of the GI
system,” said Harry L. Leider, M.D., MBA, FACPE, Chief Medical
Officer of Gelesis. “We look forward to discussing our findings
with the scientific community.”
Details of the presentations are as follows:
Poster Title: Gelesis100 Reduces Insulin Resistance in
Patients Who Are Overweight or Have Obesity with High Insulin
Resistance: Results of the GLOW StudyPoster Session: P50.
Obesity Mechanisms and Treatments PotpourriDate and Time:
March 25, 2019, (1:00 - 3:00 PM)Poster Location: Poster
Board #MON-112, ENDO Expo Hall, Ernest N. Morial Convention
Center
Poster Title: Elevated Fasting Plasma Glucose Predicts
Higher Odds for Becoming a Super-Responder with Gelesis100 in the
GLOW Pivotal Weight-Loss StudyPoster Session: P05.
Obesity Comorbidities and TherapiesDate and Time: Saturday,
March 23, 2019 (1:00 - 3:00 PM)Poster Location: Poster
Board # SAT-LB023, ENDO Expo Hall, Ernest N. Morial Convention
Center
Poster Title: Gelesis Novel, Non-Systemic, Superabsorbent
Hydrogel Improves Intestinal Barrier Function in Intestinal Injury
Pre-Clinical ModelPoster Session: P50. Obesity Mechanisms
and Treatments PotpourriDate and Time: Monday, March 25,
2019 (1:00 - 3:00 PM)Poster Location: Poster Board #
MON-LB022, ENDO Expo Hall, Ernest N. Morial Convention Center
About Gelesis 100Gelesis100 is a non-systemic,
superabsorbent hydrogel in development for the potential treatment
of overweight or obesity. It is made from two naturally derived
building blocks, modified cellulose cross-linked with citric acid,
that create a three-dimensional matrix. Orally administered in
capsules with water before a meal, Gelesis100 particles rapidly
absorb water in the stomach and homogenously mix with ingested
foods. When hydrated, Gelesis100 occupies about one-fourth of the
average stomach volume. Rather than forming one large mass, it
creates thousands of small individual gel pieces with the
elasticity (firmness) of solid ingested foods (e.g., vegetables)
without caloric value. Gelesis100 maintains its three-dimensional
structure and mechanical properties during transit through the
small intestine. Once it arrives in the large intestine, the
hydrogel is partially broken down by enzymes and loses its
three-dimensional structure along with most of its absorption
capacity. The released water is reabsorbed in the large intestine,
and the remaining cellulosic material is expelled in the feces.
Gelesis100 is considered a medical device because it achieves its
primary intended purpose through mechanical modes of action
consistent with mechanobiology constructs. Gelesis100 received a
Non-Significant Risk (NSR) designation by the FDA.
This investigational product has been studied in more than 450
patients (excluding patients treated by placebo) across five
clinical studies throughout the United States, Canada, and Europe.
Other than an increase in overall gastrointestinal adverse events
(AEs), most of which were assessed as mild, there was no difference
in the incidence and severity of AEs between the Gelesis100 and
placebo groups. In both treatment groups, most AEs were mild or
moderate in intensity. No serious adverse events were observed in
the Gelesis100 group. Gelesis100 is pending De Novo clearance
and is not available for sale in the United States.
About GelesisGelesis is developing a novel mechanobiology
platform technology to treat obesity and other chronic diseases
related to the GI pathway. Gelesis’ proprietary approach is
designed to act mechanically in the GI pathway to potentially alter
the course of chronic diseases. In September 2017, Gelesis
completed a pivotal trial for weight loss evaluating its lead
investigational product candidate Gelesis100. Additionally, Gelesis
is conducting a proof-of-concept study for its second candidate,
Gelesis200, which is optimized for weight loss and glycemic control
in patients with type 2 diabetes and prediabetes. Novel hydrogel
mechanotherapeutics based on the Gelesis platform technology are
also being advanced through a pipeline with preclinical studies in
other GI-related conditions such as non-alcoholic fatty liver
disease (NAFLD), non-alcoholic steatohepatitis (NASH), and
inflammatory bowel disease (IBD).
The Gelesis executive and advisory team includes some of the
world’s leading experts in obesity, chronic disease research, and
materials science. Gelesis was co-founded by PureTech Health (LSE:
PRTC), an advanced, clinical-stage biopharmaceutical company. For
more information, visit www.gelesis.com or connect with
us on Twitter @GelesisInc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190321005191/en/
InvestorsKathryn McNeil+1 347 204
4226kmcneil@gelesis.com
U.S. mediaTom Donovan+1 857 559
3397tom@tenbridgecommunications.com
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024